Skip to Content
Search Menu

Higher-Than-Recommended Lenalidomide Dosing Is Safe in Transplant-Eligible Newly Diagnosed Multiple Myeloma with Renal Impairment

High renal response without renal decline supports the safety and efficacy of lenalidomide doses higher than recommended during induction in transplant-eligible newly diagnosed multiple myeloma patients.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Related

Johan Gustafsson

Towards Identifying Which CLL Patients with Richter Transformation Respond to Immune Checkpoint Inhibitor Therapy

/ Johan Gustafsson
ASH25 Play the Video 4:04

Low-dose Decitabine/Cedazuridine Reduces Toxicity While Preserving Efficacy in Low-risk MDS

/ Jan Andreasen
ASH25
Signe Modvig

Danish Research Identifies Promising New Target for Preventing CNS Relapse in ALL

/ Signe Modvig
ASH25 Play the Video 03:30

BPd Preserved or Improved Quality of Life in Patients with RRMM

/ Paul G. Richardson / Jan Andreasen
ASH25Myeloma
Ingrid Cecilia Glimelius

Novel Clinical Data in Mantle Cell Lymphoma Highlighted in ASH 2025 Oral Session

/ Ingrid Cecilia Glimelius
ASH25 Play the Video 5:57
Ingrid Cecilia Glimelius

Nordic Study Uncovers a New Minimally Invasive Biomarker for Low-Risk Mantle Cell Lymphoma

/ Ingrid Cecilia Glimelius
ASH25 Play the Video 2:57
Henrik Hjorth-Hansen

Improving CML Outcomes: Nordic CML Study Group Shares New ASH 2025 Insights

/ Henrik Hjorth-Hansen
ASH25Lymphoma Play the Video 4:10
Wojciech Jurczak

Pirtobrutinib Showed Positive Efficacy and Safety vs Ibrutinib in BTKi-naïve CLL/SLL Patients Both for Treatment-naïve Patients and Patients with R/R Disease

/ Wojciech Jurczak
ASH25CLL Play the Video 7:23
Waleed Ghanima

Norwegian Study Can Change the Clinical Practice for Patients with Immune Thrombocytopenia

/ Waleed Ghanima
ASH25 Play the Video 05:57
Back to top